{"entity":{"id":"nct05573724","kind":"trial","name":"Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is completed.","summary":"The registry lists NCT05573724 as completed, last updated 2024-06-18. Enrolment is 16 actual participants. Interventions: AZD5305, Itraconazole. Primary measures include Part A: Area under the concentration-time curve from time zero to infinity (AUCinf); Part A: AUC from time zero to time of last measurable concentration (AUClast). No results are posted in the registry; this does not exclude separate publications.","status":"completed","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05573724","url":"https://clinicaltrials.gov/study/NCT05573724"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["parp"],"drugs":["saruparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05573724","phase":"1","setting":"A Non-randomized, Open-label, Fixed-sequence Phase I Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD5305 in Patients With Advanced Solid Malignancies","sponsor":"AstraZeneca","started":"2022-11-07","startedType":"actual","enrolled":16,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05573724/","neighbours":{"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}]}}